Researchers at the Leiden University Medical Center (LUMC) have uncovered how a small inherited variation in the insulin gene can reduce the risk of developing type 1 diabetes. Published in Cell, this discovery deepens understanding of the disease and paves the way for more precise, personalized treatments.
Led by Professor Bart Roep, the team found that about 40% of Dutch people carry a protective version of the insulin gene. According to Dr. René van Tienhoven—researcher and type 1 diabetes patient—this genetic variation results in “super beta cells” that can better withstand stress. When under pressure, these cells release the tension in a way that prevents them from being detected and destroyed by the immune system.
This mechanism allows the beta cells, which produce insulin, to stay healthier and function longer—essentially making them invisible to the autoimmune attack that defines type 1 diabetes. The finding offers new potential for earlier diagnosis, improved prognoses, and more targeted therapies for individuals at risk.
The Dutch Life Sciences Conference 2025 was held on 20 November 2025 at the CORPUS Congress Centre in Oegstgeest, bringing together biotech and medtech companies, academic...
The Equals campaign is an initiative promoting gender equality in technology, science, and innovation. Its goal is to shine a spotlight on talented women, raise awareness about...
Leiden, 26 November 2025 – INFECTA, a Dutch clinical research organization specializing in infectious diseases, has signed a cooperation agreement with AHAM Vastgoed for the...